Keyword »
Topic »
Author »
Date »
MARCH / APRIL 2014 :: 75(2)
Medical Imaging

Medical imaging has revolutionized screening and diagnosis, but this technology is not risk-free. As use of advanced imaging has grown, attention has increasingly focused on the risks of radiation exposure, the anxiety associated with incidental findings, and the costs of such imaging. This issue of the NCMJ will address the pros and cons of medical imaging and will discuss how this technology can be used more safely and effectively.


Dual-Energy X-Ray Absorptiometry: Overused, Neglected, or Just Misunderstood?

Andrew J. Laster

N C Med J. 2014;75(2):132-136.PDF | TABLE OF CONTENTS

Assessment of bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) plays a vital role in the diagnosis of osteoporosis and in monitoring a patient’s response to drug therapy. This commentary will discuss controversies surrounding the use of DXA for screening and monitoring of BMD in women.

The National Osteoporosis Foundation (NOF) has estimated that more than 43.6 million Americans have osteoporosis or osteopenia (low bone mass) [1]. In 2005, 2 million fractures were attributed to osteoporosis, with a direct cost of $17 billion; 71% of these fractures occurred in women [2]. By 2025, costs associated with fractures are projected to increase to $25.3 billion [2].

Bone mineral density (BMD) testing by dual-energy x-ray absorptiometry (DXA) is the recognized standard for the clinical assessment of skeletal health. DXA allows for the diagnosis of osteoporosis or low bone mass, strongly correlates with mechanical strength [3], is a good predictor of fracture risk [4], and affords excellent accuracy and precision [5] while minimizing patients’ exposure to ionizing radiation [6]. Moreover, drug therapy has been shown to be cost effective in postmenopausal women with osteoporosis [7]. Given that approximately 40% of white women older than 50 years will have an osteoporotic fracture in their lifetime [8], having clear recommendations for screening and monitoring using DXA are essential. Because of the absence of pertinent studies in men, this commentary will only address the evaluation of BMD in women.

DXA screening for low bone mass or osteoporosis is well accepted in women aged 65 years or older, regardless of risk factors, and in younger women with risk factors such as rheumatoid arthritis, glucocorticoid use, malabsorption syndromes, hyperthyroidism, hyperparathyroidism, or gastric bypass surgery. Screening of these individuals is recommended by NOF [1], the US Preventive Services Task Force (USPSTF) [9], the International Society for Clinical Densitometry (ISCD) [10], the American Association of Clinical Endocrinologists (AACE) [11], the American College of Radiology [12], and the North American Menopause Society (NAMS) [13]. Despite the fact that DXA testing has been added to the “Welcome to Medicare Exam,” only 14% of eligible women had a DXA study in 2010 [14]. Over the 7-year period from 2002 through 2008, 48% of older women did not have a DXA study [14].

Is DXA Testing Overused in Younger Women?
Potential misuse of DXA testing is a concern that has been raised by the Centers for Medicare & Medicaid Services (CMS) and the National Committee for Quality Assurance, which have together submitted for public comment a quality measure regarding “appropriate use of DXA scans in women under 65 years who do not meet the risk factor profile” [15]. The quality measure cites a small, retrospective study of 615 women [16], in which 41.3% of women younger than 65 years who had been sent for DXA screening were found to have been screened inappropriately, based on their lack of any of the recognized risk factors listed in the 2010 NAMS position statement.

However, a much larger study performed by Kale and colleagues [17] as part of the National Physicians Alliance Good Stewardship initiative found that DXA tests were ordered inappropriately in only 1.4% (95% confidence interval, 0.9%–2.2%) of all primary care visits by women aged 40–64 years. This study performed a cross-sectional analysis using 2009 data from the National Hospital Ambulatory Medical Care Survey and the National Ambulatory Medical Care Survey, which collect data on patient visits to primary care physicians in non–federally funded hospital outpatient departments and in non–federally funded, non–hospital-based offices, respectively; national estimates were then generated using weighted samples [17]. Given the large size and more rigorous methodology of this study, a critical analysis of the available data fails to support the claim that DXA testing is being misused in women younger than 65 years.

Indications for DXA Testing
What indications should be considered when determining the need for DXA testing? Table 1 provides a composite list of indications that have been proposed by AACE, ISCD, NAMS, and NOF. Table 2 lists the Medicare beneficiaries for whom CMS will cover DXA testing, based on the Balanced Budget Act of 1997 [18] and a 2006 revision of the relevant regulations [19]; although these guidelines are specific to the Medicare population, they are often adopted by private insurers as well. The 2011 updated guidelines from the USPSTF recommend DXA testing for any woman younger than 65 years if her fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors [9]. This guideline effectively sets the testing threshold at a risk level of 9.3%, which is the 10-year risk of major osteoporotic fracture for a 65-year-old white woman with a body mass index of 21 kg/m2 (found using the FRAX fracture risk assessment tool developed by the World Health Organization). To apply this guideline, FRAX is calculated without BMD, and if the 10-year risk for major osteoporotic fracture is at least 9.3%, then DXA testing would be appropriate based on the USPSTF recommendations. However, clinicians should be cautious in how rigorously they adhere to these recommendations, because clinical risk factors are a good predictor of fracture but only a fair predictor of BMD [20]. As the USPSTF points out in their guidelines, “clinicians should consider each patient’s values and preferences and use clinical judgment when discussing screening with women in this age group” (50–64 years) [9].

Repeat DXA Testing
Repeat DXA testing is also controversial, both in older women and in those younger than 65 years, whether or not they are receiving drug therapy for low bone mass or osteoporosis. CMS allows for repeat DXA testing every 2 years [19], or more frequently if it is deemed to be medically necessary. Testing more frequently than every 2 years might be medically necessary when identification of rapid bone loss could alter treatment recommendations, such as when a patient has hyperparathyroidism or will be receiving glucocorticoids for 3 months or longer. However, insurers that oversee the administration of Medicare policies within specific states (commonly referred to as local Medicare carriers) have been allowed to define the conditions under which testing is medically necessary, and some have routinely allowed repeat testing at 12-month intervals in all postmenopausal women receiving drug therapy.

The literature is divided as to whether repeat DXA testing in untreated postmenopausal women enhances our ability to predict fracture risk. Two studies [21, 22] concluded that repeat DXA testing, which allows calculation of bone density loss, provides little value beyond that of the initial BMD assessment; however, one of these studies [21] looked at a younger cohort of patients in whom the fracture rate was significantly lower and the baseline BMD was much higher. In contrast, 2 other studies [23, 24] demonstrated that bone loss detected by DXA is a predictor of fracture risk independent of baseline BMD. Moreover, we know that individuals who experience rapid bone turnover are at increased risk of fracture independent of their baseline BMD [25]. When a patient has a repeat DXA study performed on the same machine at the same institution (and the precision error is known and the least significant change has been calculated), then significant declines in BMD across several measured sites (spine and hip, or both hips) should influence decisions about drug therapy.

Controversy also surrounds the frequency of repeat testing in older women who are not being treated for low bone mass or osteoporosis. A 2012 study in The New England Journal of Medicine [26] examined DXA testing intervals in 4,957 untreated postmenopausal women aged 67 years or older who had had more than 1 DXA study and who had normal BMD or osteopenia at baseline. The primary outcome was the estimated time interval for 10% of participants to develop osteoporosis without experiencing a hip or clinical vertebral fracture or needing to start treatment for osteoporosis. Not unexpectedly, the authors found that a higher baseline BMD was associated with a longer time to develop osteoporosis and that women with normal bone density at age 67 years were unlikely to have subsequent rapid bone loss [26]. However, media reports failed to appreciate that this study excluded women in their early postmenopausal years, when accelerated bone loss might require shorter testing intervals, and it also excluded women who had osteoporosis by DXA, those who had prior fractures, and those who were already receiving drug therapy. Additionally, this study did not assess for morphometric vertebral fractures, the presence of which would have established a clinical diagnosis of osteoporosis even if densitometric criteria were consistent with osteopenia.

While media reports have suggested that frequent DXA testing is a significant problem in clinical practice, the data suggest otherwise. King and Fiorentino demonstrated that during the 7-year span from 2002 through 2008, 25.4% of elderly fee-for-service Medicare beneficiaries had only 1 DXA study, 15.4% had 2 studies, 8.1% had 3 studies, 2% had 4 studies, and less than 1% had 5 or more DXA studies. Almost half (47.87%) of the individuals in this group did not have a DXA study [14].

Finally, some researchers have challenged the role of repeat DXA testing in postmenopausal women who are receiving drug therapy. A 2009 study by Bell and colleagues assessed 6,459 women with low BMD who were enrolled in the Fracture Intervention Trial (FIT) and were randomized to receive placebo or alendronate [27]. BMD was measured at baseline and at 1, 2, and 3 years after randomization. The authors concluded that monitoring BMD in the first 3 years after starting treatment “is unnecessary and may be misleading.” Performing a secondary analysis of pooled data from the 2 arms of FIT, they determined that more than 97% of treated patients demonstrated an increase in BMD. However, Watts and colleagues [28] pointed out several flaws in the Bell study. First, they noted that the purpose of monitoring is not to document an increase in BMD but to identify people who experience a significant decline in BMD, because these individuals experience a higher rate of fracture compared with individuals whose BMD is stable or increasing. In fact, patients in FIT were dropped from the trial if they had significant bone loss in the lumbar spine or total hip (8% or more over 1 year, 10% or more over 2 years, or 12% or more over 3 years) [29]. Moreover, patients in FIT faced a number of exclusion criteria, which set them apart from a real-world treatment group, and study participants also had significantly greater compliance with alendronate.

As we sort through these studies and recommendations, we should keep in mind that DXA is not the only tool for assessing fracture risk. The presence of a prior fragility fracture establishes a clinical diagnosis of osteoporosis and warrants drug therapy even if a DXA study shows only osteopenia. Vertebral body compression fractures may be detected by a plain radiograph or with Vertebral Fracture Assessment (VFA), a software addition to DXA that provides either a single-energy or a dual-energy x-ray image of the thoracic and lumbar vertebrae. Anywhere from 16% to 48% of older individuals with osteopenia on DXA have evidence of prevalent vertebral body compression fractures, most of which are low trauma [30-32]. The presence of such fractures changes the clinical diagnosis to osteoporosis and has a significant impact on treatment decisions. Moreover, fracture risk increases as vertebral fractures increase in number and severity [33].

FRAX provides 10-year fracture risk predictions using a number of clinical risk factors in addition to BMD, and NOF provides treatment thresholds specific to the United States for patients with osteopenia [1]. Using the concept of fracture risk thresholds rather than relying solely on BMD, AACE has proposed reasonable guidelines for frequency of DXA testing in patients who are not receiving treatment for osteoporosis or low bone mass (see Table 3) [11].

Despite being a chronic disease in which prevention has been shown to save money, osteoporosis remains under-recognized and undertreated. There is little evidence to support the claim that DXA testing is widely misused in either younger women or in older women who are enrolled in Medicare. A number of studies, some of which have been inaccurately or incompletely covered in the lay press, have created confusion among health care providers and patients regarding the value of DXA testing. Compounding this confusion, there has been a 65% decline in Medicare reimbursement of DXA in the nonfacility setting, from $139 in 2006 to $49 in 2014; at this lower level, providers can no longer cover their operating costs. This has resulted in an 8.3% decline in testing rates in postmenopausal women from 2011 to 2012 (Christopher Hogan, PhD, written communication, July 2013; based on an analysis of data from the Medicare Physician/Supplier Procedure Summary Master Files, summarized from 5% Standard Analytical Files through 2012), and there has been an 8.1% decline in the number of DXA providers nationally between 2008 and 2011 (Christopher Hogan, PhD, written communication, July 2013; based on counts of unique provider identifiers on 5% sample, Limited Data Set, Standard Analytical Files, 2005–2011). Twenty-nine states lost more than 10% of their DXA providers, and 9 of those 29 states lost more than 20% of their DXA providers (Alison B. King, PhD, written communication, August 2013; based on counts of unique provider identifiers on 5% sample, Limited Data Set, Standard Analytical Files, 2005–2011).

DXA remains an important tool in the assessment of skeletal health. Critical analysis fails to support the assumption that DXA testing is overused in women less than 65 years of age. In women 65 years of age or older, the challenge is undertesting. Repeat DXA testing may be of clinical utility in untreated individuals who are approaching a fracture threshold and in treated patients to exclude significant bone loss from noncompliance, lack of efficacy, or a secondary cause of metabolic bone disease that was previously unidentified.

Potential conflicts of interest. A.J.L. is a consultant or member of the speakers’ bureau for Amgen, Novartis, and Eli Lilly. He is also past president and current chairperson of public policy for the International Society for Clinical Densitometry.

1. National Osteoporosis Foundation (NOF). 2013 Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: NOF; 2013. Accessed January 14, 2014.

2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465-475.

3. Lotz JC, Cheal EJ, Hayes WC. Fracture prediction for the proximal femur using finite element models: Part II—Nonlinear analysis. J Biomech Eng. 1991;113(4):361-365.

4. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254-1259.

5. Mazess R, Chesnut CH 3rd, McClung M, Genant H. Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int. 1992;51(1):14-17.

6. Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK. Radiation exposure in bone mineral density assessment. Appl Radiat Isot. 1999;50(1):215-236.

7. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc. 2005;53(10):1697-1704.

8. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(5 Suppl):505S-511S.

9. US Preventive Services Task Force. Screening for osteoporosis: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154(5):356-364.

10. Kendler DL, Borges JL, Fielding RA, et al. The official positions of the International Society for Clinical Densitometry: indications of use and reporting of DXA for body composition. J Clin Densitom. 2013;16(4):496-507.

11. Watts NB, Bilezikian JP, Camacho PM, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1-37.

12. American College of Radiology (ACR). ACR-SPR-SSR Practice Guidelines for the Performance of Dual Energy X-Ray Absorptiometry (DXA). 2013. Accessed January 15, 2014.

13. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54.

14. King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests’ benefit in reducing fractures. Health Aff (Millwood). 2011;30(12):2362-2370.

15. Centers for Medicare & Medicaid Services (CMS). Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile. 2013. Public Comment page, CMS Web site. Accessed January 15, 2014.

16. Schnatz PF, Marakovits KA, Dubois M, O’Sullivan DM. Osteoporosis screening and treatment guidelines: are they being followed? Menopause. 2011;18(10):1072-1078.

17. Kale MS, Bishop TF, Federman AD, Keyhani S. “Top 5” lists top $5 billion. Arch Intern Med. 2011;171(20):1856-1858.

18. Balanced Budget Act of 1997. Pub L No. 105-217, §4106a. 42 CFR 410.31.

19. Bone mass measurement: conditions for coverage and frequency standards. Fed Regist. 2006;71(231):69783-69784. Accessed January 16, 2014.

20. Ribot C, Tremollieres F, Pouilles JM. Can we detect women with low bone mass using clinical risk factors? Am J Med. 1995;98(2A):52S-55S.

21. Leslie WD, Morin SN, Lix LM; Manitoba Bone Density Program. Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab. 2012;97(4):1211-1218.

22. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155-160.

23. Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res. 2005;20(7):1195-1201.

24. Sornay-Rendu E, Munoz F, Duboeuf F, Delmas PD. Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. J Bone Miner Res. 2005;20(11):1929-1935.

25. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337-349.

26. Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225-233.

27. Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.

28. Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24(10):1643-1646.

29. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082.

30. Schousboe JT, DeBold CR, Bowles C, Glickstein S, Rubino RK. Prevalence of vertebral compression fracture deformity by X-ray absorptiometry of lateral thoracic and lumbar spines in a population referred for bone densitometry. J Clin Densitom. 2002;5(3):239-246.

31. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom. 2001;4(4):373-380.

32. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20(10):1813-1819.

33. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18(6):761-770.

Andrew J. Laster, MD, FACR, CCD assistant consulting professor, Duke University School of Medicine, Durham, North Carolina; and clinical instructor, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Address correspondence to Dr. Andrew J. Laster, Arthritis & Osteoporosis Consultants of the Carolinas, 1918 Randolph Rd, Ste 600, Charlotte, NC 28207 (